Advances in mRNA vaccines for viral diseases

Abstract

Since the onset of the pandemic caused by severe acute respiratory syndrome coronavirus 2, messenger RNA (mRNA) vaccines have demonstrated outstanding performance. mRNA vaccines offer significant advantages over conventional vaccines in production speed and cost-effectiveness, making them an attractive option against other viral diseases. This article reviewed recent advances in viral mRNA vaccines and their delivery systems to provide references and guidance for developing mRNA vaccines for new viral diseases.

mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization

“…[11][12][13][14][15] The mRNA-LNP platform can express a substantial number of antigens, which undergo MHCrestricted presentation by dendritic cells (DCs), which confers the mRNA vaccine with a potential for application in TCV approaches. 13,14,16 Moreover, mRNA molecules provide built-in adjuvant activity by stimulating Toll-like receptors. [16][17][18][19][20] The mRNA platform has pharmaceutical benefits, such as reduced production time and ease of validation; therefore, it is considered a promising TCV modality for overcoming existing challenges in vaccine research.…”

“…[8][9][10] The unprecedented success of the messenger RNA (mRNA) lipid nanoparticle (LNP) vaccine has opened a new avenue in vaccine research and development. [11][12][13][14][15] The mRNA-LNP platform can express a substantial number of antigens, which undergo MHCrestricted presentation by dendritic cells (DCs), which confers the mRNA vaccine with a potential for application in TCV approaches. 13,14,16 Moreover, mRNA molecules provide built-in adjuvant activity by stimulating Toll-like receptors.…”